RxDoctor Payments Data

Samish Dhungana, MD

Neurology · Maruetta, GANPI 1316275035

Payments from drug & device makers

$8,896in general payments, 2019–2025

Across 487 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • EMD Serono, Inc.$584
  • UCB, Inc.$473
  • Bristol Myers Squibb$364
  • AstraZeneca$327
  • Acadia Pharmaceuticals Inc$322
  • plus $5K from 53 others

What the payments were for

  • Speaking & faculty fees$2993%
  • Food & beverage$8,54796%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)169$2,255
EMD Serono, Inc.26$584
UCB, Inc.14$473
Bristol Myers Squibb13$364
AstraZeneca15$327
Acadia Pharmaceuticals Inc16$322
Amgen19$319
Eisai Inc.13$282
Novartis15$243
Pfizer9$213
Biogen12$204
Neurelis, Inc.9$200
Sanofi9$191
Supernus Pharmaceuticals, Inc.8$190
GE HealthCare11$177
Otsuka America Pharmaceutical, Inc.7$172
Neurocrine Biosciences, Inc.7$157
Teva Pharmaceuticals USA, Inc.9$156
Acorda Therapeutics, Inc7$127
Upsher-smith Laboratories LLC7$114
Grifols USA, LLC6$104
Lilly USA, LLC5$97
TG Therapeutics, Inc.3$96
Johnson & Johnson4$95
Lundbeck LLC5$92
Sunovion Pharmaceuticals Inc.5$79
Biohaven Pharmaceuticals, Inc.4$76
Jazz Pharmaceuticals Inc.3$74
Avanir Pharmaceuticals, Inc.4$69
Tanabe Pharma America, Inc.3$68
Vanda Pharmaceuticals Inc.2$63
CSL Behring3$61
E.r. Squibb & Sons, L.L.C.3$57
MDD US Operations, LLC1$55
Argenx US, Inc.3$54
Octapharma USA, Inc.3$53
Adamas Pharmaceuticals, Inc.4$53
Biohaven Pharmaceutical Holding Company Ltd.2$51
Aquestive Therapeutics, Inc.2$41
Genentech USA, Inc.2$41
Alnylam Pharmaceuticals Inc.2$38
SK Life Science, Inc.1$32
Promius Pharma LLC2$31
Axsome Therapeutics, Inc.1$31
Kyowa Kirin, Inc.2$31
Catalyst Pharmaceuticals, Inc.1$27
Arbor Pharmaceuticals, Inc.2$26
Almatica Pharma LLC2$26
Greenwich Biosciences, Inc.1$25
Sanofi-aventis U.S. LLC1$24
Amneal Pharmaceuticals LLC2$23
Sumitomo Pharma America, Inc.1$21
Bausch Health US, LLC1$20
Banner Life Sciences, LLC1$19
Aucta Pharmaceuticals, Inc.1$18
Impel Pharmaceuticals Inc.1$16
Mallinckrodt Enterprises LLC1$15
Livanova USA, Inc.1$14
Zyla Life Sciences, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,896 in reported general payments places this provider in the 70th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$171,048
Medicare patients
667
Services billed
9,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant84$89,979
Aimovig AutoinjectorErenumab-Aooe74$61,913
UbrelvyUbrogepant43$46,007
Nurtec OdtRimegepant Sulfate13$23,722
Ajovy AutoinjectorFremanezumab-Vfrm16$11,525
Sumatriptan Succinate105$10,604
Galantamine Hbr106$10,288
Memantine Hcl288$8,399
Gabapentin444$6,919
Sumatriptan12$6,840
Donepezil Hcl588$5,762
BrilintaTicagrelor11$5,710
Duloxetine Hcl158$4,595
Pregabalin218$4,564
Lacosamide36$4,385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$2,255$135,986127 claims
PfizerNurtec Odt$213$23,72213 claims
AstraZenecaBrilinta$327$5,71011 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$23$2,65530 claims
Upsher-smith Laboratories LLCTopiramate$114$2,146203 claims
Lilly USA, LLCOlanzapine$97$1,16238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 506 neurology providers in Georgia.

Other neurology in Maruetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →